CSIMarket Company Name, Ticker, Suppliers, else..
 
Allakos Inc   (ALLK)
Other Ticker:  
 
 
Price: $0.6994 $0.01 1.362%
Day's High: $0.7 Week Perf: 12.08 %
Day's Low: $ 0.65 30 Day Perf: 10 %
Volume (M): 87 52 Wk High: $ 3.41
Volume (M$): $ 61 52 Wk Avg: $1.39
Open: $0.67 52 Wk Low: $0.54



 Market Capitalization (Millions $) 61
 Shares Outstanding (Millions) 87
 Employees 131
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -166
 Cash Flow (TTM) (Millions $) -135
 Capital Exp. (TTM) (Millions $) 1

Allakos Inc
Allakos Inc. is a biopharmaceutical company based in California that specializes in the development of therapeutic antibodies for the treatment of various immune-mediated diseases. The company was founded in 2012 by Nessa Carion and Dr. Robert Alexander, and went public in 2018 (NASDAQ: ALLK).

Allakos has a unique focus on eosinophilic and mast cell-related diseases, which are conditions that result from the dysfunction of certain types of immune cells. These diseases can be chronic and debilitating, affecting multiple organ systems and leading to a host of complications.

Allakos has several drug candidates in its pipeline, with its lead product, AK002, being tested clinically for several indications, including eosinophilic gastritis and urticaria, chronic rhinosinusitis with nasal polyps, and indolent systemic mastocytosis. AK002 is an antibody that targets the cell surface receptor Siglec-8, which is expressed on eosinophils and mast cells. By binding to Siglec-8, AK002 is thought to reduce the activation and proliferation of these cells, thereby reducing inflammation and symptoms associated with the target diseases.

In addition to AK002, Allakos is also developing two other drug candidates: AK001, which targets a different receptor on mast cells, and AK003, which targets a cytokine called IL-33 that is involved in the activation of mast cells and other immune cells.

Allakos has a robust research program, with a strong focus on identifying new drug targets and developing novel therapies for unmet medical needs. The company has collaborations with academic and industry partners, including the National Institutes of Health, to leverage their expertise and resources.

Overall, Allakos is a dynamic and growing biopharmaceutical company that is making strides in developing new treatments for immune-mediated diseases. Its innovative approach and promising drug candidates have garnered attention from investors, clinicians, and patients alike.


   Company Address: 825 Industrial Road San Carlos 94070 CA
   Company Phone Number: 597-5002   Stock Exchange / Ticker: NASDAQ ALLK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Fail to Meet Primary Endpoints: Implications for Allakos' Future Development

Published Tue, Jan 16 2024 12:01 PM UTC

In recent years, the field of pharmaceutical sciences has witnessed tremendous progress in the development of novel therapeutics. One such promising candidate was lirentelimab, a drug developed by Allakos Inc., aimed at providing relief for patients suffering from atopic dermatitis and chronic spontaneous urticaria. However, despite initial optimism, the company recently ann...
Allakos Inc

Major Pharmaceutical Preparations Company, Allakos Inc., Reports Significant Reduction in Financial Performance during the Third Quarter of 2023



As the reporting season for July to September 30, 2023 continues, several businesses from various industries have released their financial numbers. One notable industry affected by recent financial challenges is Major Pharmaceutical Preparations, which includes Allakos Inc. Their recent report of an operating deficit of $-48.21 million in the fiscal third quarter of 2023 has raised concerns among investors. While the revenue figures are yet to be disclosed, comparing previous performances can provide valuable insights into the company's financial position and future prospects.
Financial Challenges and Revenue Generation:
Allakos Inc, an ascending player in the pharmaceutical industry, is currently facing a challenging period marked by mounting financial losses. To put this into perspective, in the third quarter of 2022, the company reported an operating deficit of $-31.445 million, indicating a considerable increase in losses over the last year.
Allakos Inc

Allakos Inc, a Major Pharmaceutical Preparations industry player, reports significant improvement in Q2 2023 with operating deficit reducing to $-49.117 million, showing economic enhancement despite challenging sector standards

Allakos Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently reported its earnings for the second quarter of 2023. The company disclosed an operating deficit of $-37.817 million, which may seem concerning at first glance. However, when compared to the operating deficit of $-49.117 million in the same period last year, there is a notable improvement.
This positive trend is generating optimism among analysts who see it as a promising revelation, especially considering the challenging standards faced by companies in this sector. During the financial second quarter of 2023, Allakos Inc managed to operate more economically, resulting in a reduction of diminishing returns to $-35.120 million.
Allakos Inc

ALLK Announces Improved First Quarter 2023 Performance Amidst Challenging Market

Allakos Inc. is a leading company in the pharmaceutical preparations industry. The San Carlos-based firm specializes in the development of therapeutic antibodies that address serious medical conditions associated with the immune system. Their efforts are geared towards helping patients with unmet medical needs in the treatment of diseases including urticaria, eosinophilic gastritis and other inflammatory and allergic conditions.
The earnings season for the period of January to March 2023 has resumed and the results for Allakos Inc. have been recently disclosed. The company has announced an operating deficit of $-45.046 million for the fiscal year ending March 31, 2023. However, there is cause for optimism because the losses have decreased significantly from $-197.023 million, a reduction of $154.619 million, in the first quarter of 2022.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com